The REDUCE study demonstrated a reduction in the risk of recurrent stroke with patent foramen ovale closure and antiplatelet therapy compared to antiplatelet therapy alone. The clinicians were allowed to choose among aspirin, clopidogrel, or aspirin/dipyridamole with the expectation that all antiplatelet therapies would have similar efficacy in this population. We tested that presumption by comparing recurrent stroke rates among antiplatelet agents within the control arm of the trial.
We evaluated patients in REDUCE study who were randomized to the medical arm. The primary endpoint for this analysis was freedom from clinical ischemic stroke through at least 2 years of follow-up, to a maximum of 5 years. In the primary analysis, antiplatelet treatment was defined as the agent during the week prior to a recurrent stroke or last known contact.
Of 223 patients in the medical treatment arm, the initial agent was aspirin 52%, clopidogrel 30%, and aspirin/dipyridamole 12%. Patients treated with aspirin were similar to those treated with alternatives, but were more likely to be enrolled in the United States. The last reported agent was aspirin alone in 55%, clopidogrel alone in 31%, aspirin/dipyridamole in 7%, and other/nothing/missing in 7%. Recurrent stroke rates were similar for all 3 antiplatelet regimens in unadjusted and adjusted analyses, with no overall difference among agents (P= .17).
Among patients with patent foramen ovale-associated stroke who were managed medically, there were no differences among antiplatelet agents in the risk of recurrent stroke, though confidence intervals were wide.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Stroke and Cerebrovascular Diseases
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke.N Engl J Med. 2017; 377: 1033-1042
- Patent foramen ovale closure with gore helex or cardioform septal occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: design of the randomized gore reduce clinical study.Int J Stroke. 2017; 12: 998-1004
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (caprie).Lancet. 1996; 348: 1329-1339
- European stroke prevention study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.J Neurol Sci. 1996; 143: 1-13
- Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the caprie and cure studies.JAMA Intern Med. 2004; 164: 2106-2110
- Dipyridamole for preventing recurrent ischemic stroke and other vascular events.Stroke. 2005; 36: 162-168
- An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke.Neurology. 2013; 81: 619-625
Published online: February 07, 2020
Accepted: December 22, 2019
Received: November 23, 2019
Funding: This work was supported by WL Gore and Associates.
© 2019 Elsevier Inc. All rights reserved.
ScienceDirectAccess this article on ScienceDirect
- Corrigendum to ‘Comparison of Antiplatelet Therapies for Prevention of Patent Foramen Ovale-Associated Stroke’ [Journal of Stroke and Cerebrovascular Diseases, Vol. 29, No. 4 (April), 2020: 104632]Journal of Stroke and Cerebrovascular DiseasesVol. 29Issue 8